{
    "Trade/Device Name(s)": [
        "Extended Lipid Panel Assay"
    ],
    "Submitter Information": "Laboratory Corporation of America Holdings",
    "510(k) Number": "K181373",
    "Predicate Device Reference 510(k) Number(s)": [
        "K012286",
        "K031824",
        "K873049",
        "K063608"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "CHH",
        "CDT",
        "LBS",
        "MSJ"
    ],
    "Summary Letter Date": "September 12, 2018",
    "Summary Letter Received Date": "September 13, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1175",
        "21 CFR 862.1705",
        "21 CFR 862.1475"
    ],
    "Regulation Name(s)": [
        "Cholesterol (total) test system",
        "Triglyceride test system",
        "Lipoprotein test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Cholesterol",
        "High Density Lipoprotein Cholesterol",
        "Triglycerides",
        "Apolipoprotein B"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Vantera Clinical Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Nuclear magnetic resonance (NMR)",
        "Partial Least Squares (PLS) regression model"
    ],
    "Methodologies": [
        "Spectral analysis",
        "Regression modeling"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Extended Lipid Panel Assay using NMR-based spectral analysis for quantitation of lipids and apolipoprotein B in serum and plasma",
    "Indications for Use Summary": "Quantitative determination of total cholesterol, high density lipoprotein cholesterol, and triglycerides in human serum and plasma, and apolipoprotein B in human serum, to aid in diagnosis and treatment of lipid disorders and related diseases",
    "fda_folder": "Clinical Chemistry"
}